Introduction
Inhibition of dopamine β-hydroxylase (DBH) may provide significant clinical improvement in patients suffering from cardiovascular disorders, such as hypertension and chronic heart failure. The rationale for the use of DBH inhibitors is based on their ability to inhibit the biosynthesis of norepinephrine (NE), via inhibition of the enzymatic hydroxylation of dopamine (DA) [1] .
Direct inhibition of sympathetic nerve function by reducing the biosynthesis of NE, preventing the conversion of DA to NE in sympathetic nerves, and possibly by increasing the release of DA, can induce renal vasodilation, diuresis, and natriuresis. β-adrenergic blockers are no longer recommended as primary therapy for hypertension except for patients with coexisting conditions, such as coronary heart disease or left ventricular dysfunction. α-adrenergic blockers are also not recommended as first-line therapy for hypertension because they may be associated with increased incidence of adverse cerebrovascular and cardiovascular outcomes [2] . Therefore, inhibitors of DBH may provide significant clinical advantages over other drug treatments, especially those that affect the sympathetic nervous system.
Etamicastat [(R)-5-(2-aminoethyl)-1-(6,8-difluorochroman-3-yl)-1,3-dihydroimidazole-2-thione hydrochloride] is a potent, reversible inhibitor of peripheral DBH with limited access to the brain [1] . In spontaneously hypertensive rats (SHRs) but not in normotensive control rats, oral administration of etamicastat lowered both systolic and diastolic blood pressures in a dose-dependent manner without affecting the heart rate [3] . Etamicastat, chronically administered in drinking water, also significantly reduced both blood pressure and urinary NE excretion but increased urinary DA excretion in the SHR [4] . This DBH inhibitor has also been shown to decrease blood pressure in hypertensive patients [5] .
The intrarenal dopaminergic system plays an important role in the normal regulation of renal sodium excretion and blood pressure [6, 7] . Human essential hypertension and some rodent models of genetic hypertension are associated with decreased renal DA production and receptor function [6, 8] . Both DA D2-like (Drd2, Drd3, and Drd4) and D1-like (Drd1 and Drd5) receptors have been shown to regulate arterial blood pressure. Abnormalities of the D 2 R gene (DRD2) play a role in the pathogenesis of human essential hypertension; several variants of the human DRD2 have been reported to be associated with hypertension [9, 10] and disruption (D 2 −/− ) or renal-selective silencing of Drd2 in mice increases systolic and diastolic blood pressures [11] [12] [13] and may cause salt sensitivity [14] . The hypertension of D 2 −/− mice has been related to increased sympathetic and vascular smooth muscle endothelin B receptor (ETBR) activities [11] , as well as increased reactive oxygen species (ROS) [12] . In this study, we determined the effects of inhibition of DBH and NE formation with etamicastat on blood pressure in D 2 −/− mice. We measured blood pressure in conscious and anesthetized D 2 −/− mice and D 2 +/+ littermates after acute-and short-term administration of etamicastat, catecholamine levels in the heart, kidney, and urine, and renal expression of selected G protein-coupled receptor and enzymes related to and a parameter of ROS production. In addition, we studied the effect of etamicastat on the elevated blood pressure of mice in which renal cortical Drd2 was silenced by the renal subcapsular infusion of Drd2-specific small interfering RNA (siRNA), via an osmotic minipump [13] . We also determined the expression of selected sodium transporters, exchangers, and channels in the kidney of D 2 −/− mice and D 2 +/+ littermates before and after treatment with etamicastat.
Materials and methods

D 2 receptor-deficient mice
The original F2 hybrid strain (129/SvXC57Bl/6J, Oregon Health Sciences University, Portland) that contained the mutated D 2 R allele (D 2 −/− ) was backcrossed into wild-type C57Bl/6J for >20 generations and genotyped [10] . [17, 18] . Etamicastat (10 mg/kg per day) or vehicle (tap water) was added in the drinking water after baseline blood pressure measurement. The mice were monitored for 5 days after starting drug treatment. Blood pressure and heart rate were recorded every 10 min throughout the study. Data were collected and stored automatically in a dedicated computer that ran and analyzed the data (Dataquest). Thereafter, the mice were killed, kidneys were collected and the renal expression of selected G protein-coupled receptors, ROS-related enzymes, and selected sodium transporters, exchangers, and channels were quantified, as reported [11, 12, [17] [18] [19] [20] [21] [22] [23] .
In another study, mice implanted with TA-PAC20 transmitters were treated with etamicastat (10 mg/kg per day in the drinking water) for 5 days and fed a normal salt (0.6% NaCl) diet. At the end of this period, the dose of etamicastat was increased to 50 mg/kg per day for another 5 days. Blood pressure was recorded (one reading per h) on the last day on each treatment.
Acute renal-specific downregulation of D 2 R Renal cortical Drd2 was silenced by the renal subcapsular infusion of Drd2-specific siRNA, via an osmotic minipump [13, 19, 20] . Adult male C57BL/6J mice were uninephrectomized 1 week before the implantation of the minipump. Osmotic minipumps (ALZET ® Osmotic Pump, 100 µl; flow rate 0.5 µl/h for 7 days) were filled with previously validated Drd2-specific siRNA (delivery rate 3 μg per day) or non-silencing siRNA as control. The siRNAs were dissolved in an in vivo transfection reagent (TransIT ® In Vivo
Gene Delivery System, Mirus) under sterile conditions. The minipumps were fitted with a polyethylene delivery tubing (Alzet #0007701) and the tip of the tubing was inserted within the subcapsular space of the remaining kidney. Etamicastat treatment (10 mg/kg per day in the drinking water) was started immediately after pump implantation. Blood pressure was measured under pentobarbital anesthesia, as described, 7 days after pump implantation.
Immunoblotting
Whole-kidney lysates were prepared in lysis buffer supplemented with protease inhibitors, as previously reported [11, 12, [17] [18] [19] [20] [21] [22] [23] . Samples with equal amounts of proteins were separated by 10% SDS-polyacrylamide gel (Bio-Rad) electrophoresis and transferred onto nitrocellulose membranes. The membranes were sequentially probed with the primary antibodies (1:5000) at 4°C overnight and corresponding horseradish peroxidase-conjugated secondary antibodies (1:10,000, Pierce at room temperature for 1 h). Chemiluminescence was detected using SuperSignal West Dura Substrate (Thermo Fisher Scientific, Waltham, MA), followed by autoradiography. The band densities of the proteins of interest were quantified by the NIH Image J and normalized by corresponding total actin bands. Alternatively, for infrared detection of protein signal, the membranes were probed with Infra-red dye 680-or 800-labeled secondary antibodies (Li-COR Bioscience, Lincoln, NE). The band densities of the proteins of interest were quantified using the Odyssey Infrared imaging system (Li-COR) and normalized by corresponding total actin bands. The rabbit polyclonal antibodies against DA receptors D 1 R (DRD1), D 3 R (DRD3), D 4 R (DRD4), and D 5 R (DRD5) were generated in our laboratory while rabbit polyclonal antibodies against D 2 R (EMD Millipore, Billerica, MA) and actin (Sigma-Aldrich, St. Louis, MO) were purchased. We have reported the specificity of our D 1 R antibody [18, 20] , D 3 R antibody [19] , D 4 R antibody [17] , D 5 R antibody [21, 22] , D 1 R antibody from Origene (Rockville, MD) [22] , and D 2 R from EMD Millipore [13] . The sources of other antibodies used were: NHE3, NKCC2, NCC, αENaC, βENaC, γENac, generous gifts of Dr. Mark Knepper [21] ; ETBR (Alomone Labs, Jerusalem, Israel); NOX1 (NADPH Oxidase 1, Santa Cruz Biotechnologies, Dallas, TX), NOX2 (gp91 phox, Upstate Biotech/Thermo Fisher Scientific), and HO-1 (Enzo Life Sciences, Farmingdale, NY).
Assay of catecholamines
Catecholamines in urine and tissue (DA and NE) were assayed by high-performance liquid chromatography with electrochemical detection, as previously described. The lower limit of detection of DA and NE is 350 fmol [1, 15] .
Assay of 8-isoprostane
Urinary isoprostane, a parameter of oxidative stress, was measured by enzyme immunoassay (Cayman Chemical Company, Ann Arbor, MI) [12] . Values were corrected for urinary creatinine.
Statistical analysis
Data are reported as mean ± SEM. Comparisons between two groups used the Student's t test. One-way analysis of variance, followed by Holm-Sidak test, was used to assess significant differences among three or more groups. P < 0.05 was considered statistically significant.
Results
Etamicastat Systolic blood pressure measured by telemetry in conscious mice was also higher in D 2 −/− than D 2 +/+ mice (Fig. 1b) . Administration of etamicastat (10 mg/kg per day, n = 4-5 per group), added to the drinking water, also decreased systolic blood pressure in D 2 −/− mice but had no significant effect in D 2 +/+ littermates. The decrease in systolic blood pressure was noted 24 h after starting treatment and persisted throughout the duration of the study (Fig. 1b) . The decrease in systolic blood pressure was more marked during the night when the mice are awake, feeding, and drinking water (Fig. 1c) . The conscious systolic blood pressure during the day or night was similar in mice treated for 5 days with a 10 or 50 mg/kg per day dose of etamicastat.
Renal cortical-selective silencing of the D 2 R increased blood pressure in mice [13] . As shown in Fig. 2a , in mice implanted with an osmotic minipump for the continuous renal subcapsular infusion of D 2 R siRNA, renal D 2 R expression was decreased to about 70% as we have reported previously [13] . These mice have increased systolic blood pressure under anesthesia. The increase in blood pressure resulting from the D 2 R siRNA infusion was prevented in mice treated with etamicastat in the drinking water (10 mg/ kg per day, n = 5 per group) during the 7 days of D 2 R siRNA infusion (Fig. 2b) . , two-way ANOVA followed by Holm-Sidak test Fig. 2 Effect of etamicastat on blood pressure in mice with renalselective silencing of the D 2 R. a Renal cortical expression of D 2 R in the remnant kidney of adult male uninephrectomized C57Bl/6J mice treated with a renal subcapsular infusion of Drd2 siRNA or nonsilencing (NS) siRNA for 7 days (n = 6 per group; P < 0.05, Student's t test). b Renal cortical Drd2 was silenced by the renal subcapsular infusion of Drd2 siRNA, via an osmotic minipump for 7 days in uninephrectomized adult male C57Bl/6J mice (Methods). Etamicastat (ETAM, 10 mg/kg per day in the drinking water) treatment was started immediately after pump implantation. Blood pressure was measured under anesthesia before and 7 days after pump implantation. n = 5 per group; *P < 0.05 vs all others; one-way ANOVA followed by Holm-Sidak test. (Fig. 3c) .
Effect of etamicastat on the renal expression of dopamine and endothelin B receptors
In D 2 −/− mice, relative to D 2 +/+ littermates, the renal protein expressions of D 3 R and ETBR were increased. Etamicastat treatment did not alter the increased renal expression of D 3 R, but increased D 1 R expression, normalized ETBR expression, and decreased D 5 R expression (Fig. 4a, b , n = 4-5 per group). 
Effect of etamicastat on the renal expression of ROS-related enzymes
In agreement with our previous report [12] , the renal expressions of NADPH oxidase isoforms NOX1 and NOX2 were increased in D 2 −/− mice, relative to D 2 +/+ littermates.
Treatment with etamicastat normalized the expression of these NOX isoforms but did not affect HO-1 expression in D 2 −/− mice (Fig. 5a , b, n = 4-5 per group). Moreover, the urinary excretion of isoprostane, a product of the nonenzymatic oxidation of arachidonic acid, and a marker of oxidative stress, was increased in vehicle-treated D 2 −/− mice and was almost completely normalized by etamicastat treatment ( Fig. 6 ; n = 4 per group).
Effect of etamicastat on the expression of selected renal sodium cotransporters, exchangers, and channels in D 2 −/− mice
The renal protein expressions of sodium hydrogen exchanger type 3 (NHE3) and sodium chloride with an increase in the DA/NE content in heart and urine (but not kidney) and D 1 R expression in the kidney, as well as a normalization of renal NOX isoforms (NOX1 and NOX2) and proximal tubule NHE3 and a decrease in distal convoluted tubule NCC. These could be taken to indicate that the increase in urinary DA does not reflect total renal DA but is specific to the nephron segment where DA is produced, i.e., renal proximal tubule. The DA produced in the renal proximal tubule is secreted in the tubular lumen affecting sodium transporters beyond the proximal tubule [6] . The reduction in blood pressure in hypertensive D 2 −/− mice agrees with the reported ability of etamicastat to decrease blood pressure in hypertensive rats and humans [3] [4] [5] . The hypertension in D 2 −/− mice is, in part, related to increased sympathetic activity proved by the ability of α1-adrenergic receptor blockade and adrenalectomy to decrease the elevated blood pressure of D 2 −/− mice to the same level as that noted in D 2 +/+ littermates [11] . The two models we have used in this study are different in that one involves global germ line deletion of the D 2 R while the other involves a 7-day renal subcapsular infusion of Drd2 siRNA in the remaining kidney of uninephrectomized mice that decreases renal D 2 R expression by 60-70%. Hemodynamic changes to compensate for the uninephrectomy may increase sympathetic nervous activity and potentiate the effect of D 2 R silencing. In fact, we have reported that uninephrectomy plus silencing of D 2 R in the remnant kidney increases blood pressure to the same extent as that observed with global deletion of the gene; the same period (1 week) of siRNA infusion in one kidney while the other kidney is unperturbed has no significant effect on blood pressure [13] . However, if the D 2 R siRNA is infused for 28 days instead of 7 days, the blood pressure increases to the same extent as the global germ line deletion of D 2 R [24] . These results point to a predominant role of the kidney in the hypertension that develops in mice with deficient D 2 R function. The NE content of the heart (but not kidney) was increased in vehicle-treated D 2 −/− mice, which may reflect the increased sympathetic activity in these mice [11, 25] . Etamicastat treatment of these D 2 −/− mice significantly decreased cardiac NE and increased cardiac DA. In wildtype littermates treated with etamicastat, there was a trend for NE to decrease and DA to increase, but the effects were not statistically significant. In previous studies using etamicastat, the decrease in DBH activity and sympathetic drive was associated with a decrease in NE in the heart of wild-type mice [1] and urine in healthy human subjects [26] . In the current study, cardiac NE content was decreased by 40% in D 2 −/− mice but minimally in D 2 +/+ , 18 h after administration of a 10 mg/kg dose of etamicastat. This modest decrease may be due to differences in sympathetic activity between D 2 −/− and D 2 +/+ mice [11, 27] . By contrast, it has been shown that, in normal mice, a 100 mg/kg dose of etamicastat decreased heart NE content by 75% [1] . Deletion of the Dbh gene in mice is associated with NE deficiency. However, the extracellular levels of DA are also decreased in the nucleus accumbens and caudate putamen but not in the prefrontal cortex and increased in adrenergic neurons, cerebellum, liver, lung, retina, skeletal muscle, and spleen of Dbh −/− mice on mixed C57BL/6 and 129/SvEv background [28, 29] . Urine NE and DA levels, were similar in D 2 −/− and their wild-type littermates, in agreement with our previous report [11] and with the failure of others to find differences in DA levels in the brain striatum of D [25] , this result may suggest that the inhibitory effect of etamicastat is more pronounced or of longer duration in the heart than in the kidney. It is also possible that the failure of etamicastat to decrease NE content in the kidney may be related to the fact that DA produced by the renal proximal tubule is not converted to NE; renal proximal tubules do not express DBH (see below). The increase in blood pressure in D 2 −/− mice is not due to an increase in the activity of the renin-angiotensin system [11] . However, we have reported that the hypertension in D 2 −/− mice is associated with increased production of ROS, accompanied by increased expression of NOX enzymes, results that were corroborated in the present study [12] . Treatment with etamicastat normalized the renal expression of NOX enzymes and almost normalized the levels of ROS, as determined by urinary levels of 8-isoprostane. In D 2 −/− mice, treatment with spironolactone decreased blood pressure, and normalized the increased expression of NOX1 and NOX4 but had no effect on the increased NOX2. Thus, it is possible that the increase in blood pressure in D 2 −/− mice drives the increase in NOX isoforms expression. In tissues outside the central nervous system, the inhibition of DBH increases DA release [32, 33] ; DA has vasorelaxant effects that cause an increase in renal blood flow and indirectly abets the increase in sodium excretion caused by direct inhibition of renal tubular sodium transport [6] . Independent of innervation, the kidney synthesizes DA that is not metabolized to NE and prevents the ability of moderate sodium load to increase blood pressure by inducing diuresis and natriuresis [6, 34] . Cardiac and urinary DA levels are increased in D 2 −/− mice after etamicastat administration. In spite of the fact that DA produced by the kidney from L-DOPA is not metabolized to NE because DBH is not expressed in renal tubules [35] , inhibition of DBH could still increase renal DA because of blockade of NE production from renal nerves [36] . Most if not all the DA in the urine is synthesized in the kidney (specifically in the proximal tubules) under normal conditions [6, 36, 37] . However, an increase in DA release in peripheral tissues, caused by inhibition of DBH by etamicastat may substantially increase DA in the circulation, and thus, in the glomerular filtrate (Fig. 8) . The increase in the DA/NE ratio in the urine in both groups could also reflect an increase in renal production of DA. In fact, it has been reported that in patients with congenital DBH deficiency, not only is free plasma DA increased but also plasma DOPA that would increase the substrate for the synthesis of urinary DA [38] . DA increases renal sodium excretion, in part, by inhibiting renal NHE3, sodium phosphate cotransporters (NaPiIIa, NaPi-IIc), Cl -/HCO 3 − exchanger, sodium bicarbonate exchanger (NBCe1), NaKATPase, NCC, ENaC, and potassium channel [6] . Treatment with etamicastat reversed the increased renal protein expressions of NHE3, NCC, and ETBR protein in D 2 −/− mice suggesting that these changes were secondary to either the increased sympathetic activity or blood pressure. However, etamicastat also increased renal D 1 R expression, did not alter the increased D 3 R expression and decreased D 5 R expression in D 2 −/− mice, indicating some specific effect on renal DA receptor expression when renal/urinary DA is increased. The human DRD2 gene encoding the D 2 R is highly polymorphic. The presence of some single-nucleotide polymorphisms (SNPs; rs6276, rs6277, and rs1800497) in the DRD2 gene are associated with decreased D 2 R expression and function attributable to decreased D 2 R messenger RNA stability and synthesis of the receptor and are associated with elevated blood pressure and hypertension [10, 39] . These SNPs are highly prevalent with minor allele frequencies ranging from 0.24 to 0.47 [40] . From the pharmacogenomics point of view, etamicastat would be ideal to treat hypertensive patients carrying these SNPs.
In conclusion, etamicastat is effective in normalizing blood pressure in D 2 −/− mice, in which hypertension is caused, in part, by increased activity of the sympathetic nervous system. In D 
